תפריט ראשי עליון

תפריט עמוד

Talk To Us

Full name {{ClubFormCtrlAlias.ValidationObj.required}}

Full name - {{ClubFormCtrlAlias.ValidationObj.textBoxChars}}

Full name - {{ClubFormCtrlAlias.ValidationObj.inputToShort}}

Full name - {{ClubFormCtrlAlias.ValidationObj.ContactNameTooLong}}

{{500 - ClubFormCtrlAlias.MailContactUS.Description.length}} characters remaining of 500

More info {{ClubFormCtrlAlias.ValidationObj.required}}

More info - {{ClubFormCtrlAlias.ValidationObj.FreeText}}

More info - {{ClubFormCtrlAlias.ValidationObj.inputToShort}}

More info - {{ClubFormCtrlAlias.ValidationObj.DescriptionTooLong}}

{{ClubFormCtrlAlias.ServiceMsgResponse}}
Research & Development

​Hematology Research Laboratory for Extracellular Vesicles at The Morris Kahn Personalized Medicine Research Center

​The Hematology Research Laboratory for Extracellular Vesicles at the Morris Kahn and recent Center was established On Nov. 2017. Dr. Anat Aharon, who led the Extracellular discoveries Vesicles Research Laboratory at the Rambam Healthcare Campus in Haifa for 14 years, joined the Sourasky Medical Center to establish the lab and lead its team.

Dr. Aharon and her team study the roles of Extracellular Vesicles (EVs), small (~1 μm) cellular membrane vesicles that are shed from various cells in several diseases and pathologies.
Specifically, the research focus on hematological malignancies such as myeloma, acute myeloid leukemia (AML), in patients with chronic graft vs. host disease (cGVHD), solid tumors and in congenital disorders such as thalassemia.
In these studies, we demonstrated that EVs affect and reflect disease dynamics and may be used not only for diagnosis and monitoring of therapy, but also can serve as part of a
treatment.
In our recent published study (1) we demonstrated that EVs of multiple myeloma cells utilize proteasome inhibitor mechanism to moderate endothelial angiogenesis.

Other projects in the lab 

  • The use of EVs as a marker for early disease relapse and study the opportunity to use EVs measurable residual disease in patients with acute leukemia;
  • Defining the immunomodulation-therapeutic characteristics of EVs obtained from patients with cGVHD, treated with mesenchymal stem cells (MSCs).
  • The Role of Microvesicles in the Patho-physiology and Complications of Beta Thalassemia (supported by ISF grant), recent publication (2).
  • Extracellular vesicles of colon cancer patients during adjuvant chemotherapy as potential biomarker
  • Extracellular vesicles of Alzheimer’s disease patients as a biomarker for disease progression.


Publications

1. Zarfati M, Avivi I, Brenner B, Katz T, Aharon A. Angiogenesis. Extracellular vesicles
of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate
endothelial angiogenesis. 2018 Nov 1. doi: 10.1007/s10456-018-9649-y.
2. Levin C, Koren A, Rebibo-Sabbah A, Koifman N, Brenner B, Aharon A. Extracellular
Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional
Status and Ineffective Erythropoiesis. Front Physiol. 2018;9:1214
3. Aharon  A,  Rebibo Sabbah A. Issman L. BerkovichH. Copty R. Talmon Y, Brenner B. Effects of Low- and High-Dose Chemotherapy Agents on Thrombogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines Thrombosis and Hemostasis march 2018
4. Aharon  A,  Sabbah A, Ben-Shaul S, Berkovic H, David Loven D, Brenner B and Bar-Sela B. Chemotherapy administration to breast cancer patients affects extracellular vesicles thrombogenicity and function. Oncotarget 2017 8:63265-63280
5. Aharon  A,  Sabbah A, Issman L,  Berkovic H, Stern H, Abboud Y, Talmon Y, Brenner B.   Effects of Low- and High-Dose Chemotherapy on Tumorigenic, Thrombogenic and Angiogenic Properties of Extracellular Vesicles Derived from Breast Cancer Cell Lines. –Submitted to Breast Cancer Research, April  2017 
6. Tzoran I, Rebibo-Sabbah A. Brenner B, Aharon, A.  Disease dynamics in patients with acute myeloid leukaemia: new biomarkers. Excepted for publication in Exp Hematol. 2015;43:936-43
7. Shomer E, Katzenell S, Zipori Y, Sammour RN, Isermann B, Brenner B, Aharon A. Microvesicles of Women With Gestational Hypertension and Preeclampsia Affect Human Trophoblast Fate and Endothelial Function. Hypertension. 2013; 62: 893-8.


Collaborations

  • Sourasky Medical Center: Laboratory for Cancer Research and Immunotherapy, Surgery Research Laboratory
  • Rambam Health Care Campus: Oncology Department, Cognitive Unit, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology.
  • Emek Medical Center: Pediatric Hematology Unit and Laboratory Research.


Group members

Lab Manager: Anat Aharon, PhD
Students: Shlomit Limon- PhD Student, Einav Zaggi-Rom 


Fig. 1.
The role of microvesicles (MVs) in cancer. Cell exposure to stimulators such as chemotherapy, radiation,
cytokines and thrombin results in release of MVs from tumour cells as well as the host cells  (Aharon A. Best Pract Res Clin Haematol. 2009)


Fig. 2. Scanning electron microscopy (SEM) images of extracellular vesicles (EVs) shedding from breast cancer 

cells before stimulation (A-D) and after stimulation (E). ( Aharon A. Thromb Haemost. 2018 )




Department details

Sammy Ofer Heart Building
Floor 10

תפריט ניווט תחתון